Clinicians typically classify meningiomas—the most common type of brain tumor—into three grades, ranging from slow-growing to aggressive. But a new multi-institutional study suggests that appearances may be deceiving. If a tumor shows activity in a gene called telomerase reverse transcriptase, it tends to recur more quickly, even if it looks low-grade under the microscope.
FDA granted accelerated approval for Modeyso (dordaviprone) for the treatment of adult and pediatric patients (1 year of age and older) with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
